Description
Switch therapy, or the transition from intravenous to oral antibiotics, is shown to be effective and highly cost-saving when applied early in treatment.
Cefixime, with its strong safety and efficacy profile, has demonstrated excellent outcomes in studies, allowing patients to switch after 2–3 days of IV therapy without compromising results. Beyond lowering drug and hospital costs, the approach reduces complications linked to prolonged IV use and improves patient comfort and quality of life.
For broader adoption, experts emphasize the need for clear guidelines and greater awareness among healthcare providers.